Shyeilla V Dhuria

US Patent:

20080305077, Dec 11, 2008

Filed:

Jun 6, 2008

Appl. No.:

12/134385

Inventors:

Leah Ranae Bresin Hanson - Vadnais Heights MN, US
Shyeilla V. Dhuria - Minneapolis MN, US

Assignee:

HealthPartners Research Foundation - Bloomington MN

International Classification:

A61K 38/20
A61K 38/28
A61K 33/24
A61K 31/225
A61P 31/00
A61P 25/00
A61K 31/16
A61P 25/28
A61P 37/00
A61P 35/00
A61K 31/22
A61K 38/18

US Classification:

424 852, 514 4, 514 12, 424646, 514546, 514547, 514616

Abstract:

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.

US Patent:

20180125940, May 10, 2018

Filed:

Nov 2, 2017

Appl. No.:

15/801437

Inventors:

- Bloomington MN, US
Leah Ranae Bresin Hanson - Vadnais Heights MN, US
Shyeilla V. Dhuria - Minneapolis MN, US

International Classification:

A61K 38/20
A61K 38/18
A61K 33/24
A61K 9/00
A61K 45/06
A61K 38/28
A61K 31/16
A61K 38/30
A61K 38/19

Abstract:

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter glia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.